Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）

Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
L & L biopharma Co., Ltd., Shanghai China